Antimicrobial Activity of Ceftaroline and Other Anti-Infective Agents against Microbial Pathogens Recovered from the Surgical Intensive Care Patient Population

A Prevalence Analysis

Charles E. Edmiston, Candace J. Krepel, David Leaper, Nathan A. Ledeboer, Tami-lea Mackey, Mary Beth Graham, Cheong J. Lee, Peter J. Rossi, Kellie R. Brown, Brian D. Lewis, Gary R. Seabrook

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Ceftaroline is a new parenteral cephalosporin agent with excellent activity against methicillin-sensitive (MSSA) and resistant strains of Staphylococcus aureus (MRSA). Critically ill surgical patients are susceptible to infection, often by multi-drug-resistant pathogens. The activity of ceftaroline against such pathogens has not been described.

Methods: Three hundred thirty-five consecutive microbial isolates were collected from surgical wounds or abscesses, respiratory, urine, and blood cultures from patients in the surgical intensive care unit (SICU) of a major tertiary medical center. Using Clinical and Laboratory Standards Institute (CLSI) standard methodology and published breakpoints, all aerobic, facultative anaerobic isolates were tested against ceftaroline and selected comparative antimicrobial agents.

Results: All staphylococcal isolates were susceptible to ceftaroline at a breakpoint of ≤1.0 mcg/mL. In addition, ceftaroline exhibited excellent activity against all streptococcal clinical isolates and non-ESBL-producing strains of Enterobacteriaceae (93.5%) recovered from SICU patients. Ceftaroline was inactive against ESBL-producing Enterobacteriaceae, Pseudomonas aeruginosa, vancomycin-resistant enterococci, and selective gram-negative anaerobic bacteria.

Conclusions: At present, ceftaroline is the only cephalosporin agent that is active against community and healthcare-associated MRSA. Further studies are needed to validate the benefit of this novel broad-spectrum anti-infective agent for the treatment of susceptible serious infections in the SICU patient population.
Original languageEnglish
Pages (from-to)745-751
Number of pages7
JournalSurgical Infections
Volume15
Issue number6
Early online date4 Jun 2014
DOIs
Publication statusPublished - 15 Dec 2014
Externally publishedYes

Fingerprint

Critical Care
Anti-Infective Agents
Population
Intensive Care Units
Enterobacteriaceae
Cephalosporins
Staphylococcus aureus
Gram-Negative Anaerobic Bacteria
Community Health Services
Methicillin
Infection
T 91825
Critical Illness
Abscess
Pseudomonas aeruginosa
Urine
Pharmaceutical Preparations

Cite this

Edmiston, Charles E. ; Krepel, Candace J. ; Leaper, David ; Ledeboer, Nathan A. ; Mackey, Tami-lea ; Graham, Mary Beth ; Lee, Cheong J. ; Rossi, Peter J. ; Brown, Kellie R. ; Lewis, Brian D. ; Seabrook, Gary R. / Antimicrobial Activity of Ceftaroline and Other Anti-Infective Agents against Microbial Pathogens Recovered from the Surgical Intensive Care Patient Population : A Prevalence Analysis. In: Surgical Infections. 2014 ; Vol. 15, No. 6. pp. 745-751.
@article{392fbadd80bf4741a53f1a380acb3471,
title = "Antimicrobial Activity of Ceftaroline and Other Anti-Infective Agents against Microbial Pathogens Recovered from the Surgical Intensive Care Patient Population: A Prevalence Analysis",
abstract = "Background: Ceftaroline is a new parenteral cephalosporin agent with excellent activity against methicillin-sensitive (MSSA) and resistant strains of Staphylococcus aureus (MRSA). Critically ill surgical patients are susceptible to infection, often by multi-drug-resistant pathogens. The activity of ceftaroline against such pathogens has not been described.Methods: Three hundred thirty-five consecutive microbial isolates were collected from surgical wounds or abscesses, respiratory, urine, and blood cultures from patients in the surgical intensive care unit (SICU) of a major tertiary medical center. Using Clinical and Laboratory Standards Institute (CLSI) standard methodology and published breakpoints, all aerobic, facultative anaerobic isolates were tested against ceftaroline and selected comparative antimicrobial agents.Results: All staphylococcal isolates were susceptible to ceftaroline at a breakpoint of ≤1.0 mcg/mL. In addition, ceftaroline exhibited excellent activity against all streptococcal clinical isolates and non-ESBL-producing strains of Enterobacteriaceae (93.5{\%}) recovered from SICU patients. Ceftaroline was inactive against ESBL-producing Enterobacteriaceae, Pseudomonas aeruginosa, vancomycin-resistant enterococci, and selective gram-negative anaerobic bacteria.Conclusions: At present, ceftaroline is the only cephalosporin agent that is active against community and healthcare-associated MRSA. Further studies are needed to validate the benefit of this novel broad-spectrum anti-infective agent for the treatment of susceptible serious infections in the SICU patient population.",
keywords = "Antimicrobial activity, Ceftaroline, Anti-infective agents, Surgical intensive care patients, Prevalence analysis",
author = "Edmiston, {Charles E.} and Krepel, {Candace J.} and David Leaper and Ledeboer, {Nathan A.} and Tami-lea Mackey and Graham, {Mary Beth} and Lee, {Cheong J.} and Rossi, {Peter J.} and Brown, {Kellie R.} and Lewis, {Brian D.} and Seabrook, {Gary R.}",
year = "2014",
month = "12",
day = "15",
doi = "10.1089/sur.2013.172",
language = "English",
volume = "15",
pages = "745--751",
journal = "Surgical Infections",
issn = "1096-2964",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

Edmiston, CE, Krepel, CJ, Leaper, D, Ledeboer, NA, Mackey, T, Graham, MB, Lee, CJ, Rossi, PJ, Brown, KR, Lewis, BD & Seabrook, GR 2014, 'Antimicrobial Activity of Ceftaroline and Other Anti-Infective Agents against Microbial Pathogens Recovered from the Surgical Intensive Care Patient Population: A Prevalence Analysis', Surgical Infections, vol. 15, no. 6, pp. 745-751. https://doi.org/10.1089/sur.2013.172

Antimicrobial Activity of Ceftaroline and Other Anti-Infective Agents against Microbial Pathogens Recovered from the Surgical Intensive Care Patient Population : A Prevalence Analysis. / Edmiston, Charles E.; Krepel, Candace J.; Leaper, David; Ledeboer, Nathan A.; Mackey, Tami-lea; Graham, Mary Beth; Lee, Cheong J.; Rossi, Peter J.; Brown, Kellie R.; Lewis, Brian D.; Seabrook, Gary R.

In: Surgical Infections, Vol. 15, No. 6, 15.12.2014, p. 745-751.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antimicrobial Activity of Ceftaroline and Other Anti-Infective Agents against Microbial Pathogens Recovered from the Surgical Intensive Care Patient Population

T2 - A Prevalence Analysis

AU - Edmiston, Charles E.

AU - Krepel, Candace J.

AU - Leaper, David

AU - Ledeboer, Nathan A.

AU - Mackey, Tami-lea

AU - Graham, Mary Beth

AU - Lee, Cheong J.

AU - Rossi, Peter J.

AU - Brown, Kellie R.

AU - Lewis, Brian D.

AU - Seabrook, Gary R.

PY - 2014/12/15

Y1 - 2014/12/15

N2 - Background: Ceftaroline is a new parenteral cephalosporin agent with excellent activity against methicillin-sensitive (MSSA) and resistant strains of Staphylococcus aureus (MRSA). Critically ill surgical patients are susceptible to infection, often by multi-drug-resistant pathogens. The activity of ceftaroline against such pathogens has not been described.Methods: Three hundred thirty-five consecutive microbial isolates were collected from surgical wounds or abscesses, respiratory, urine, and blood cultures from patients in the surgical intensive care unit (SICU) of a major tertiary medical center. Using Clinical and Laboratory Standards Institute (CLSI) standard methodology and published breakpoints, all aerobic, facultative anaerobic isolates were tested against ceftaroline and selected comparative antimicrobial agents.Results: All staphylococcal isolates were susceptible to ceftaroline at a breakpoint of ≤1.0 mcg/mL. In addition, ceftaroline exhibited excellent activity against all streptococcal clinical isolates and non-ESBL-producing strains of Enterobacteriaceae (93.5%) recovered from SICU patients. Ceftaroline was inactive against ESBL-producing Enterobacteriaceae, Pseudomonas aeruginosa, vancomycin-resistant enterococci, and selective gram-negative anaerobic bacteria.Conclusions: At present, ceftaroline is the only cephalosporin agent that is active against community and healthcare-associated MRSA. Further studies are needed to validate the benefit of this novel broad-spectrum anti-infective agent for the treatment of susceptible serious infections in the SICU patient population.

AB - Background: Ceftaroline is a new parenteral cephalosporin agent with excellent activity against methicillin-sensitive (MSSA) and resistant strains of Staphylococcus aureus (MRSA). Critically ill surgical patients are susceptible to infection, often by multi-drug-resistant pathogens. The activity of ceftaroline against such pathogens has not been described.Methods: Three hundred thirty-five consecutive microbial isolates were collected from surgical wounds or abscesses, respiratory, urine, and blood cultures from patients in the surgical intensive care unit (SICU) of a major tertiary medical center. Using Clinical and Laboratory Standards Institute (CLSI) standard methodology and published breakpoints, all aerobic, facultative anaerobic isolates were tested against ceftaroline and selected comparative antimicrobial agents.Results: All staphylococcal isolates were susceptible to ceftaroline at a breakpoint of ≤1.0 mcg/mL. In addition, ceftaroline exhibited excellent activity against all streptococcal clinical isolates and non-ESBL-producing strains of Enterobacteriaceae (93.5%) recovered from SICU patients. Ceftaroline was inactive against ESBL-producing Enterobacteriaceae, Pseudomonas aeruginosa, vancomycin-resistant enterococci, and selective gram-negative anaerobic bacteria.Conclusions: At present, ceftaroline is the only cephalosporin agent that is active against community and healthcare-associated MRSA. Further studies are needed to validate the benefit of this novel broad-spectrum anti-infective agent for the treatment of susceptible serious infections in the SICU patient population.

KW - Antimicrobial activity

KW - Ceftaroline

KW - Anti-infective agents

KW - Surgical intensive care patients

KW - Prevalence analysis

U2 - 10.1089/sur.2013.172

DO - 10.1089/sur.2013.172

M3 - Article

VL - 15

SP - 745

EP - 751

JO - Surgical Infections

JF - Surgical Infections

SN - 1096-2964

IS - 6

ER -